ACT34-CMI, bone marrow-derived cells for ischemic heart diseases

ACT34 are autologous CD34+ bone marrow-derived cells used to treat myocardial ischemia (MI). The CD34+ cells are injected back into the patients. ACT34-treated MI patients have reduced angina frequency and improved exercise tolerance, however cell mobilization and collection procedures are associated with elevation in cardiac enzyme levels.